title: Preconception antiretroviral therapy and birth defects: what is needed?
authors.affiliation: aDepartment of Defense HIV/AIDS Prevention Program, Naval Health Research Center, San Diego, California bDivision of Global HIV/AIDS, Center for Global Health cDivision of Birth Defects and Developmental Disabilities, National Center on Birth Defects and Developmental Disability, Centers for Disease Control and Prevention, Atlanta, Georgia dOffice of the Global AIDS Coordinator, U.S. State Department, Washington, District of Columbia, USA.
authors.forename: Marc
authors.initials: M
authors.lastname: Bulterys
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Berry
authors.forename: D Heather
authors.initials: DH
authors.lastname: Watts
mesh_terms: D044966:Anti-Retroviral Agents / Q000008:administration & dosage* / Q000009:adverse effects*; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects* / Q000379:methods*; D000013:Congenital Abnormalities / Q000453:epidemiology*; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D018445:Infectious Disease Transmission, Vertical / Q000517:prevention & control; D011247:Pregnancy
chemical_list: D044966:Anti-Retroviral Agents